Acute dystonia is a movement disorder characterized by involuntary muscle contractions that lead to repetitive movements or abnormal postures. These contractions can be painful and are often caused by a sudden onset of muscle spasms. Acute dystonia can affect any part of the body, including the neck (cervical dystonia), eyes (oculogyric crisis), jaw or tongue, and the limbs. The condition can have varying causes, including:
- Drug-induced Dystonia: One of the most common causes. It can occur as a side effect of certain medications, particularly antipsychotic drugs that affect dopamine pathways in the brain.
- Idiopathic Dystonia: Where the cause is unknown
- Secondary Dystonia: Resulting from an underlying medical condition such as Wilson's disease, Huntington's disease, Parkinson's disease, brain injury, or stroke
Market Dynamics:
The global acute dystonia market is driven by the rising prevalence of neurological disorders that can induce acute dystonia like Parkinson's disease, cerebral palsy, and tardive dyskinesia. For instance, on August 9, 2023, according to a report published by the World Health Organization (WHO), Parkinson’s disease (PD) is a brain condition that causes problems with movement, mental health, sleep, pain, and other health issues. Nearly one million people in the U.S. were living with Parkinson's disease (PD) in 2021, while this number is expected to rise to 1.2 million by 2030. Parkinson's disease is the second-most common neurodegenerative disease after Alzheimer's disease.
Furthermore, in March 2022, according to a report published by the National Center for Biotechnology Information, cerebral palsy occurs in 2.3 to 3.6 out of every 1,000 children in the U.S., every year. While spastic cerebral palsy is the most common, making up 61 percent to 76.9 percent of all cerebral palsy cases.
Key Features of the Study:
- This report provides an in-depth analysis of the global acute dystonia market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acute dystonia market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Fresenius Kabi, Amar Healthcare, Johnson & Johnson ,PAI Pharma, Pfizer Inc., Souvin Pharmaceuticals Pvt.Ltd, Bayer Healthcare, S.S.Pharmachem, Remedy Labs, Wan Bury, F. Hoffmann-La Roche Ltd, Bausch Health Companies, Inc., Viatris Inc. , Teva Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global acute dystonia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute dystonia market
Detailed Segmentation:
- Global Acute Dystonia Market, By Drug Class
-
- Anticholinergic Agents
- Benzodiazepines
- Others (Neurotoxin, etc.)
- Global Acute Dystonia Market, By Age Group
-
- Global Acute Dystonia Market, By Distribution Channel
-
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Acute Dystonia Market, By Region
-
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Top Companies in the Global Acute Dystonia Market:
-
- Fresenius Kabi
- Amar Healthcare
- Johnson & Johnson
- PAI Pharma
- Pfizer Inc.
- Souvin Pharmaceuticals Pvt.Ltd
- Bayer Healthcare
- S.Pharmachem
- Remedy Labs
- Wan Bury
- F.Hoffmann-La Roche Ltd
- Bausch Health Companies, Inc.
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd
- Torrent Pharmaceuticals Ltd.
- Mallinckrodt Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Ltd.
